One-year follow-up of combined customized therapy. photodynamic therapy and bevacizumab for exudative age-related macular degeneration

Retina

Volumn 29, Issue 1, 2009, Pages 13-19

  Navea, Amparo ^a   Mataix, Jorge ^a   Desco, M Carmen ^a   Garcia Pous, Maria ^a   Palacios, Elena ^a  

^a Fundacion Oftalmologica del Mediterraneo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; EXUDATE; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; RELAPSE; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; VISION; VISUAL ACUITY; DRUG ANTAGONISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; RETINA MACULA DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; EXUDATES AND TRANSUDATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; RETREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 61549135108     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31818a1fd3     Document Type: Article

References (23)

1. Treatment of age-related macular degeneration with photody-namic therapy (TAP) Study Group (TAP-1). Therapy of sub-foveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 Randomized Clinical Trials-TAP Report-1. Arch Ophthalmol 1999;117: 1329-1345.
2. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photo-dynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Oph-thalmol 2001;119:198 -207.
3. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegabtanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
6. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
7. Ruiz Moreno JM, Montero J, Barile S, Zarbin M. Photody-namic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration 1-year outcome. Retina 2006;26:602-612.
8. Aggio FB, Melo GB, Hofling-Lima AL, Eid Farah M. Photo-dynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmol Scand 2006;84:831-833.
9. Heier JS, Boyer DS, Ciulla TA, et al; FOCUS Study Group. Ranibi-zumab combined with verteporfin photodynamic therapy in neovas-cular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-1542.
10. Ahmadieh H, Taei R, Soheilian M, et al. Single-session pho-todynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007;7:10.
11. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-140.
12. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photo-dynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Oph-thalmol 2001;119:198 -207.
13. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432- 1444.
14. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-993.
15. Ladas ID, Kotsolis AI, Papakostas TD, et al. Intravitreal bev-acizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina 2007;27:891-896.
16. Lazic R, Gabric N. Verteporfin therapy and intravitreal bev-acizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185.
17. Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlinge-mann RO. Vascular endothelial growth factors and angiogén-esis in eye diseases. Prog Retin Eye Res 2003;22:1-29.
18. Ferrara N, Gerber H-P, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003;9:660-676.
19. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165.
20. Calvo-González C, Reche-Frutos J, Donate-López J, et al. Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovas-cularisation in age related macular degeneration. Br J Ophthal-mol 2008;92:74-75.
21. Regillo CD, Brown DM, Abraham P, et al. The PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-248.
22. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intra-vitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
23. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control the angiogenic response to basic fibroblast growth factor. FASEB J 2004;18:1050-1059.